Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
- Conditions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3234
- Registration Number
- NCT00617019
- Locations
- 🇺🇸
248.619.01035 Emory University, Atlanta, Georgia, United States
🇺🇸248.619.01014 Northwestern University, Chicago, Illinois, United States
🇺🇸248.619.01015 John Hopkins Hospital, Baltimore, Maryland, United States
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
- Conditions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 754
- Registration Number
- NCT00615992
- Locations
- 🇦🇹
Boehringer Ingelheim Investigational Site, Wolkersdorf, Austria
Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole
- Conditions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1645
- Registration Number
- NCT00615914
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Zama, Japan
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 246
- Registration Number
- NCT00615563
- Locations
- 🇵🇷
Boehringer Ingelheim Investigational Site, Ponce, Puerto Rico
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy
- Conditions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT00615290
- Locations
- 🇫🇷
1182.127.3301 Boehringer Ingelheim Investigational Site, Strasbourg, France
🇫🇷Boehringer Ingelheim Investigational Site, Villeneuve St G, France
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
- Conditions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3148
- Registration Number
- NCT00615108
- Locations
- 🇨🇳
Boehringer Ingelheim Investigator Site 3, Taipei, Taiwan
🇨🇳Boehringer Ingelheim Investigator Site 5, Taipei, Taiwan
🇨🇳Boehringer Ingelheim Investigator Site, Miaoli, Taiwan
Special Survey on PD Patients With Renal Dysfunction
- Conditions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 107
- Registration Number
- NCT00613756
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yufu, Japan
Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population
- Conditions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 428
- Registration Number
- NCT00614302
- Locations
- 🇮🇹
Boehringer Ingelheim Investigational Site, Torino, Italy
Open Label Study Telmisartan and Amlodipine in Hypertension
- Conditions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 976
- Registration Number
- NCT00614380
- Locations
- 🇨🇦
1235.7.20013 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada
🇨🇦1235.7.20014 Boehringer Ingelheim Investigational Site, Etobicoke, Ontario, Canada
🇩🇰1235.7.45002 Boehringer Ingelheim Investigational Site, Birkerød, Denmark
RUSSE / Russian Spiriva® Safety & Efficacy Study
- Conditions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 407
- Registration Number
- NCT00613574
- Locations
- 🇷🇺
Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation